NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation
about
Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbinet10c12 conjugated linoleic acid suppresses HER2 protein and enhances apoptosis in SKBr3 breast cancer cells: possible role of COX2.Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherinTNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype.Glycogen synthase kinase-3β, NF-κB signaling, and tumorigenesis of human osteosarcoma.Mn porphyrin in combination with ascorbate acts as a pro-oxidant and mediates caspase-independent cancer cell death.Cross-regulation between FOXA1 and ErbB2 signaling in estrogen receptor-negative breast cancerExpression of functional toll like receptor 4 in estrogen receptor/progesterone receptor-negative breast cancer.Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression analysis.X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity.The interaction between ER and NFκB in resistance to endocrine therapy.Non-canonical NF-κB pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinomaRole of NF-κB as a Prognostic Marker in Breast Cancer : A Pilot Study in Indian PatientsA new cross-talk between the aryl hydrocarbon receptor and RelB, a member of the NF-kappaB familySyndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathwaysEmerging EGFR antagonists for breast cancer.Bisphenol A activates EGFR and ERK promoting proliferation, tumor spheroid formation and resistance to EGFR pathway inhibition in estrogen receptor-negative inflammatory breast cancer cells.Estrogen receptor α in cancer associated fibroblasts suppresses prostate cancer invasion via reducing CCL5, IL6 and macrophage infiltration in the tumor microenvironment.Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.Identification of frequent somatic mutations in inflammatory breast cancer.Antimetastatic effect of nobiletin through the down-regulation of CXC chemokine receptor type 4 and matrix metallopeptidase-9.Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer.High-throughput profiling of tissue and tissue model microarrays: Combined transmitted light and 3-color fluorescence digital pathology.Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced diseaseThe tumor microenvironment and inflammatory breast cancer.Redefining the role of peripheral LPS as a neuroinflammatory agent and evaluating the role of hydrogen sulphide through metformin intervention.Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges.Molecular mechanisms of hormone resistance of breast cancer.
P2860
Q28554790-A40E4B47-5801-4C9E-A715-C0C875C702ACQ30862407-CE78A333-4F64-4640-B91D-C9EC768D5083Q33317058-7CCD332F-7E0F-4DA1-B04F-27D48799F101Q34130168-69F002E8-24B4-4873-B613-D49A63A284C7Q34637826-B9714537-E102-481D-A534-153E301D9E92Q35496324-F44ACB1C-F540-44FD-8263-7260A53856F3Q35949760-86E44F1E-4DAF-4C94-A3F7-B22CFBBFAF9EQ36082731-82FA7A23-A985-4883-95C6-978BDD1E3635Q36611440-EC017091-B138-47CF-8E78-12831157F804Q36751784-F4D4D72A-3FCC-4790-B6C7-A4E4BECE6BF5Q36924406-DCEF132C-06DD-44B3-AF99-302E0A804D18Q37151107-340013EB-51FE-4790-AE91-32754373809BQ37165541-E90FFDB5-AE44-47B8-ACFF-69B16EA46FA2Q37207403-1742A208-B089-451C-B031-1749C7A13EBFQ37686006-411F7909-242D-4D64-8CF8-2D0B8D936E81Q38211951-5E29D8C1-416D-4941-A19B-BB4D96A126ACQ38706762-EA0E7F41-810D-4B1A-AC7C-AC05D5F299D5Q38801346-4567011B-855F-4F7E-B7BE-8C8465250C81Q38803734-91DE7E6C-AAEB-4164-BAAA-572FC26DCAB8Q38938061-E48268C8-0543-49F9-A326-FE60DE998F25Q39304192-3652E94F-26D5-4801-82C5-FFC4792CCFE4Q39430345-6B12E36F-2897-4EE0-A550-967AF74964C0Q39766695-A263A838-DC2B-4E4E-9E74-2275D8687D0DQ41136265-852CC697-0964-460A-AFC6-40E31873B103Q41396244-8C7597B6-C90D-48EB-960F-6711CA04C1CFQ48589396-A5192F98-C4C9-46E2-9B1E-E5F5FEDD2877Q49887925-6F188AFF-EFA0-414D-B2EE-D6B8D0D4DB56Q53086084-77BAA1DD-2884-4055-90DA-249DF3BD58BC
P2860
NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
NF-kappaB activation in inflam ...... ssion and MAPK hyperactivation
@ast
NF-kappaB activation in inflam ...... ssion and MAPK hyperactivation
@en
NF-kappaB activation in inflam ...... ssion and MAPK hyperactivation
@nl
type
label
NF-kappaB activation in inflam ...... ssion and MAPK hyperactivation
@ast
NF-kappaB activation in inflam ...... ssion and MAPK hyperactivation
@en
NF-kappaB activation in inflam ...... ssion and MAPK hyperactivation
@nl
prefLabel
NF-kappaB activation in inflam ...... ssion and MAPK hyperactivation
@ast
NF-kappaB activation in inflam ...... ssion and MAPK hyperactivation
@en
NF-kappaB activation in inflam ...... ssion and MAPK hyperactivation
@nl
P2093
P2860
P356
P1476
NF-kappaB activation in inflam ...... ssion and MAPK hyperactivation
@en
P2093
E A Van Marck
G G Van den Eynden
I Van der Auwera
P B Vermeulen
S J Van Laere
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603906
P407
P577
2007-09-03T00:00:00Z
P5875
P6179
1047148376